Please assess the completion status of the following clinical trial:

Trial Title: Impact of Misoprostol on Blood Loss In Myomectomy Operations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal patients aged between 35 to 50 years old.~* Five or less symptomatic uterine myomas .~* Maximum diameter of the largest myoma is 6 cm .~* All myomas are subserous or intramural.~* Uterine size less than 24 weeks pregnancy~Exclusion Criteria:~* History of previous surgery.~* Allergy to Misoprostol.~* Hypertension.~* Cardiac and Pulmonary diseases.~* Patients who have bleeding disorders.~* Anemia (Hb \< 10g %).~* Chronic endocrine or metabolic diseases such as Diabetes.~* Obesity (body mass index \> 30 kg/m2).~* Cases that will require intraoperative conversion of myomectomy to hysterectomy.

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Myomectomy, rectal Misoprostol (Type: EXPERIMENTAL): 25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation.
- Myomectomy, Placebo (Type: ACTIVE_COMPARATOR): Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.

Based on this trial design, predict the completion outcome and termination type (if applicable).